Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer

 
• By Jessica Merrill

The combination of Opdivo and Yervoy showed a survival advantage in renal cancer in a Phase III trial, adding to the understanding that overall survival may be a better endpoint than progression-free survival for measuring immuno-oncology drugs.

Digital illustration of Cancer cell in colour background

More from Immuno-oncology

More from Anticancer